Test Guide Mobile Home
Search: Search

PML-RARalpha Transcript Detection by PCR
Also known as : [15;17],[RT-PCR],[t(15;17)]


DNA/RNA
Test performed by: LabPLUS - Dept. Diagnostic Genetics - Molecular Haematology


Specimen Collection

NOTE:

Do not collect samples on a Friday, the weekend or the day falling immediately prior to a long weekend. These samples may be rejected and a re-collect required.

RNA is highly unstable and specimens degrade rapidly. For optimum results samples should be sent in CPD tubes at room temperature and be received by this lab within 24 hours of collection. Although LabPlus operates 24 hours a day, 7 days a week, the Molecular Haematology section only operates 9-5, Mon-Fri (excluding public holidays). Samples arriving on a Friday afternoon or a Saturday or Sunday may not get processed until the following Monday. Such delays can significantly compromise the quality of the sample.


CPD

9 mL CPD Blood (Preferred)

CPD

2 mL CPD Bone Marrow (Preferred)

EDTA

9 mL EDTA Blood

EDTA

2 mL EDTA Bone Marrow
Turnaround Time: Within 2 weeks, 4 days
Diagnostic Use and Interpretation

This PCR tests for the presence of the fusion transcript resulting from the t(15;17) (q22;q21) chromosomal translocation.


Contact Information

To contact the Molecular Haematology team please call:

Auckland City Hospital (09) 307 4949
Lablink ext 22000
Prof. Peter Browett (Haematologist) ext 9090-86281
Dr. Imogen Caldwell (Haematologist) ext 22006
Nikhil Ghallayan (Section Leader) ext 22005
Molecular Haematology Office ext 22005

For more information about the Molecular Haematology service at LabPLUS:

Molecular Haematology information page



FISH
Test performed by: LabPLUS - Dept. Diagnostic Genetics - Cytogenetics


A FISH (fluorescent in situ hydridisation) based assay is also available for this test.

Refer to Molecular Cytogenetics Probe List




Information on the PML-RARalpha Translocation:

This PCR tests for the presence of the fusion transcript resulting from the t(15;17) (q22;q21) chromosomal translocation. Primers were designed by the European BIOMED-1 Concerted Action group. This group was comprised of 14 laboratories from eight European countries who had the aim of setting up an international standardization of the protocols for the investigation of minimal residual disease in acute leukaemia.

References:
Biondi A. et al Leukemia 1999; 13: 1915-1917


Last updated at 15:36:59 07/03/2024